Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,143 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04758507 | Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma(TACITO) | completed | Phase 1 / Phase 2 | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT00930033 | Clinical Trial to Assess the Importance of Nephrectomy(CARMENA) | completed | Phase 3 | 452 | Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Sep 5, 2025 |
| clinicaltrials |
| NCT05263245 | The Pharmacological Effects of Using Cabozantinib With a Light Breakfast(Skippy 1) | completed | Phase 2 | 12 | dr. Tom van der HulleOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06582849 | Enhanced Assistance During Radiotherapy for Unmet Essential Needs(EARN) | completed | N/A | 33 | Washington University School of MedicineOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07117786 | Computed Tomography Radiomics-Derived Nomogram for Predicting Early Renal Function Decline After Partial Nephrectomy in Renal Cell Carcinoma: A Multicenter Development/Validation Study | completed | — | 1,437 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 0 | Aug 12, 2025 | clinicaltrials |
| NCT03685448 | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)(UNICAB) | completed | Phase 2 | 35 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03967522 | Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases(CABRAMET) | completed | Phase 2 | 26 | Centre Leon BerardOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT04825834 | DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)(DELFI-L101) | completed | — | 2,992 | Delfi Diagnostics Inc.INDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | completed | Phase 1 | 260 | Incyte CorporationINDUSTRY | 4 | Aug 5, 2025 | clinicaltrials |
| NCT02684006 | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | completed | Phase 3 | 886 | PfizerINDUSTRY | 21 | Jul 30, 2025 | clinicaltrials |
| NCT04508725 | Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) | completed | N/A | 22 | Stanford UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04627064 | ABEMA Alone or in COMBO With MK-6482 | completed | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 164 | Michael B. Atkins, MDOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02821793 | Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer(PRIORITY) | completed | — | 346 | Institut BergoniéOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT04006405 | AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC(AUR87A) | completed | — | 280 | ElyptaINDUSTRY | 11 | Jun 15, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT03297593 | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 74 | Swiss Cancer InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04337970 | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT02899078 | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 31 | University of California, DavisOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT02318771 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | completed | Phase 1 | 41 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02440334 | Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation | completed | Phase 2 | 53 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04802824 | Measuring Treatment Response in Metastatic Renal Cell Cancer Using FPIA PET/CT | completed | — | 10 | Imperial College LondonOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03324373 | Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) | completed | Phase 1 | 11 | Yousef ZakhariaOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04804813 | Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma | completed | — | 388 | TakedaINDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03301493 | Genomic Testing and Resulting Medical Decisions | completed | — | 1,500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT03173560 | Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | completed | Phase 2 | 343 | Eisai Inc.INDUSTRY | 16 | Apr 1, 2025 | clinicaltrials |
| NCT00720941 | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma(COMPARZ) | completed | Phase 3 | 1,110 | Novartis PharmaceuticalsINDUSTRY | 14 | Mar 30, 2025 | clinicaltrials |
| NCT06903260 | Robot-assisted Partial Nephrectomy With and Without Mixed Reality (REALITATEM Study) | completed | Phase 3 | 45 | Hospital Moinhos de VentoOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT01147822 | Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 367 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 28, 2025 | clinicaltrials |
| NCT05650164 | Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) | completed | — | 171 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06883565 | Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study | completed | — | 232 | Ding-Wei YeOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06876584 | The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy | completed | — | 1,474 | Du LingzhiOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT03149822 | Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 45 | University of Colorado, DenverOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT03891485 | Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy(REVOLUTION) | completed | — | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT01767636 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01130519 | A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer | completed | Phase 2 | 83 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06829888 | Percutaneous Tumor Ablation Vs Partial Nephrectomy for Small Renal Mass: the Impact of Histologic Variant and Tumor Size(CRYO-BO-2021) | completed | — | 955 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 0 | Feb 17, 2025 | clinicaltrials |
| NCT04043975 | A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan | completed | — | 286 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT03473730 | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | completed | Early Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06791863 | Visceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study on Postoperative Survival | completed | — | 1,030 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 8, 2025source: clinicaltrials